Analyst firms · Oppenheimer · REGN
Oppenheimer REGN price target and rating history
Regeneron Pharmaceuticals Inc. (REGN) · Health Care
Oppenheimer rates Regeneron Pharmaceuticals Inc. (REGN) Perform with a $1,050 price target, as of its latest action on Aug 21, 2023. It has published 3 rating actions on REGN since August 2021, including 0 upgrades and 0 downgrades. Across 9 firms with a REGN price target in the last 12 months, the median target is $798.
- Current rating
- Perform
- Price target
- $1,050
- Median target, all firms
- $798
- Actions on REGN
- 3
Oppenheimer price target on REGN
Every Oppenheimer rating on REGN
- Aug 21, 2023
- Feb 8, 2022
- Aug 6, 2021
How other firms rate REGN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Buy | $850 | Oct 1, 2026 |
| Citigroup | Neutral | $700 | May 18, 2026 |
| Leerink Partners | Market Perform | $641 | May 18, 2026 |
| Piper Sandler | Overweight | $875 | Mar 31, 2026 |
| Barclays | Overweight | $923 | Mar 6, 2026 |
| BofA Securities | Buy | $860 | Jan 7, 2026 |
| Morgan Stanley | Equal-Weight | $767 | Dec 3, 2025 |
| Truist Securities | Buy | $798 | Nov 24, 2025 |
| HSBC | Buy | $255 | Nov 24, 2025 |
Questions about Oppenheimer and REGN
- What is Oppenheimer's price target for REGN?
- Oppenheimer's latest stated price target for Regeneron Pharmaceuticals Inc. (REGN) is $1,050, from its action on Aug 21, 2023.
- What is Oppenheimer's rating on REGN?
- Oppenheimer rates REGN Perform, a neutral rating, as of Aug 21, 2023.
- When did Oppenheimer last change its view on REGN?
- On Aug 21, 2023, Oppenheimer raises its price target to $1,050 from $950, keeps Perform.
- How does Oppenheimer's REGN target compare with other analysts?
- Across 9 firms with a REGN price target in the last 12 months, the median target is $798.
More REGN rating histories
- Citigroup3
- Leerink Partners9
- BofA Securities3
- Morgan Stanley7
- Truist Securities3
- Bernstein3
- Raymond James3
- Jefferies3
- The Benchmark Company3
- H.C. Wainwright5
All Oppenheimer ratingsREGN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.